Skip to main contentSkip to footer
lab-16
Brighton & Sussex Medical School

PhD opportunities

BSMS > Postgraduate > Research degrees > PhD opportunities

PhD opportunities

All our current PhD studentship opportunities are listed on this page. 

In order to apply, please visit the University of Brighton website by clicking the “Apply Now” link below, and select “Doctoral College” as the School. You should then select the project that you wish to apply for. 

Apply for your PHD here >

We are also happy to consider applications from self-funded individuals, and for personally developed projects, we recommend an approach to a lead supervisor, following which you will have help and support with your application. 

For self-funded and speculative applications, we require that you submit a research proposal alongside your application. Within this you should take the opportunity to clearly outline your research idea; your research methodology and critical approaches; experience; and original contribution to knowledge and key themes, concepts and ideas. See our guidance on writing a research proposal >

BACKGROUND IMAGE FOR PANEL

Measuring the brain’s energy dynamics in order to establish crucial biomarkers for mood disorders

Supervisors: Dr Iris Asllani, Dr Alessandro Colasanti

Application deadline: Tuesday 30 April 2024

About the Project

The brain is one of the most metabolically active organs in the body, consuming a disproportionately large amount of energy compared to its size. Measuring its energy dynamics is essential for understanding brain function and addressing various mood disorders, such as bipolar disorder and schizophrenia, where dysregulation of brain energy metabolism is implicated. This PhD project aims to advance our understanding of these disorders by developing a robust, multi-modal Magnetic Resonance Imaging (MRI) method for in vivo assessment of the brain's energy dynamics specifically tailored for mood disorder applications. By capturing the key components of brain energy dynamics through imaging, we seek to construct a model that sheds light on the underlying mechanisms of mood disorders. Such efforts are critical for the advancement of more effective treatments.

The PhD student involved in this project will collaborate with a diverse team of researchers, including neuroscientists, psychiatrists, and MRI physicists. Our MRI centre offers an ideal environment for cutting-edge translational research. The campus is located in the lively coastal city of Brighton, offering students a variety of opportunities for engagement in diverse activities both on and off-campus. 

Funding Notes

The studentship will be funded for a 3-year duration. The funding will cover home fees, a stipend at the UKRI rate, and research costs of up to £3,000 per annum. If a ‘top-up’ to international fees is required, this must be provided by the applicant from their own funds or external sources.

How to apply

In order to apply, please visit the University of Brighton website, and select “Doctoral College” as the School, and you will see the project listed to apply directly.

References

BACKGROUND IMAGE FOR PANEL

Unravelling the role of gain (1q) in Multiple Myeloma

Supervisors: Dr John Jones, Dr Simon Mitchell, Prof Erika Mancini

Closing date: Friday 12 April 2024

Applications are invited for a 3-year funded PhD studentship at Brighton and Sussex Medical School.

Project details

We are looking for an enthusiastic and motivated PhD student to join our expanding research team at Brighton and Sussex Medical School. The candidate will work closely with scientists and clinicians who have extensive expertise in myeloma, oncogenesis, genetics, biochemistry, computational biology, and mathematical modelling. The focus of the project will be on determining how having an extra copy of the chromosomal 1q region (gain1q) imparts its effect on myeloma pathogenesis and treatment resistance.

Multiple Myeloma is a genetically diverse disease characterised by the malignant transformation of antibody secreting plasma cells. It accounts for approximately 10% of haematological malignancies and 2% of all cancers. Despite improvements in therapy and outcome, relapse is almost universal.

We, and others, have previously shown that a key feature of relapse, is the emergence of treatment resistant clones, characterised by the acquisition of new mutations and structural chromosome abnormalities (1 - 3). A key driver of aggressive disease, treatment resistance and clonal evolution is the presence of gain1q (4). Gain(1q) is found in 40% of patients at diagnosis and a greater proportion of patients at relapse. The reasons why gain(1q) leads to a poor prognosis is unknown.

In this project, the successful applicant will utilise genetic, biochemical, structural biology and mathematical approaches to determine how gain(1q) imparts its effect on malignant plasma cell behaviour. We will recruit patients with myeloma who are being treated in East Sussex NHS Trust Hospitals. Ethical approval is already in place and sample biobanking is underway, in preparation for project commencement. The successful applicant will learn a broad range of laboratory techniques including, bone marrow sample processing, cell culture, RNA-seq, whole exome sequencing, flow cytometry and mass spectrometry. In addition, the student will become proficient in bioinformatic modelling of the data analysed, data presentation and graphical representation. Full training will be provided.

The student will be based in the Medical Research Building on the University of Sussex Campus, in Brighton. The supervisory team will include Dr Simon Mitchell and Dr Mancini who have vast experience in structural biology, oncogenesis, mathematical systems biology and protein-protein interactions, and Dr Jones, Consultant Haematologist, who has clinical expertise in myeloma and myeloma genetics. In addition, the project will include collaboration and supervision with the broader Clinical and Experimental Medicine Team, including internationally renowned experts, Professors Andrea and Chris Pepper. The project will compliment other projects, including work on long non-coding RNA in gain(1q) myeloma, with input from RNA experts Professor Sarah Newbury and Dr Ben Towler. This is an exciting to join an expanding laboratory, including forging links with King’s College Hospital, and collaborators in the US and Europe.

Entry requirements

This studentship is suitable for those with background in biological, cancer sciences or another relevant subject area. We invite applications from students who have received or are on target to achieve a relevant undergraduate degree with minimum 2:1 classification (or equivalent). An MSc and previous laboratory experience are desirable but not essential.

How to apply

Applicants must apply through the University’s application portal where they can submit a CV and complete the application form. Please select “Doctoral College” as the School. The deadline for applications is 12 April 2024. Interviews will be held in May 2024. Informal enquiries are welcome and should be submitted to Dr John Jones (j.jones2@bsms.ac.uk). Please note, this studentship is one of three studentships being simultaneously advertised by researchers within the Haematology Research Group. We welcome parallel applications to these exciting training opportunities.

Funding Notes

This is a 3-year PhD studentship funded by Brighton and Sussex Medical, starting on 1st October 2024. Funding will cover tuition fees for UK students (at the Home rate), a stipend at the UKRI rate and a research allowance which will cover research running costs. International applicants are welcome to apply but will be required to cover the difference between Home and International fees.

References

  • Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019 Jul;104(7):1440-1450.
  • Jones JR, Barber A, Le Bihan YV, Weinhold N, Ashby C, Walker BA, Wardell CP, Wang H, Kaiser MF, Jackson GH, Davies FE, Chopra R, Morgan GJ, Pawlyn C. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia. 2021 Oct;35(10):3017-3020.
  • Jones JR, Charlotte Pawlyn, Niels Weinhold, Timothy Cody Ashby, Brian A Walker, Christopher P. Wardell, David Cairns, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Mark T Drayson, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan, The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse, Blood, Volume 138, Supplement 1, 2021, Page 2683, ISSN 0006-4971
BACKGROUND IMAGE FOR PANEL

How we might we best support dyslexic medical students and foundation doctors in safe and effective prescribing?

Supervisors: Prof Michael Okorie, Dr Sebastian Shaw, Prof Nicola Martin, Prof Gordon Ferns

Application closing date: Thursday 28 March 2024

About the Project

Foundation doctors are responsible for most of the prescribing of medicines in the acute care setting in the United Kingdom, and unsurprisingly they also have the highest prescribing error rate in comparison to more experienced prescribers. Furthermore, medical students do not feel adequately prepared for prescribing in the foundation years after graduation. Dyslexia is a specific learning difference that related to reading and writing without impacting on intelligence. Prescribing is a complex task and may be more challenging for dyslexic doctors than for their non-dyslexic peers. One study has demonstrated that medical students requiring reasonable adjustments underperform in the national Prescribing Safety Assessment in terms of both score and pass-rate. Further research is required to better understand the possible reasons for this.

Little is known about the social world of dyslexic doctors in relation to both the learning and undertaking of the prescribing of medicines. This PhD studentship is aimed at beginning to fill this dearth of research. The successful applicant will be supported in undertaking both qualitative and quantitative approaches to research in this subject area, which will culminate in a national survey of the experiences of dyslexic medical students and foundation doctors in relation to the prescribing of medicines.

Methods

1) Literature review. This will include transferable concepts from related disciplines.

2) Focused ethnographic study. The doctoral candidate will recruit 15-25 dyslexic FY1/FY2 doctors for this stage. Data will be collected in the following ways:

  • Direct participant observation in clinical settings
  • In situ interviews
  • Focus group discussions

3) Questionnaire validation study. The doctoral candidate will create and validate an online questionnaire, using the findings from the ethnographic study. The primary aim of this survey will be to quantify our qualitative findings. This will be piloted and validated for the following:

  • Content validity
  • Face validity
  • Test-retest reliability

4) National survey of medical students and foundation doctors using the validated questionnaire.

Research Plan

Phase 1: A review of existing policy and literature surrounding prescribing education, the act of prescribing in clinical settings and dyslexia in medicine/medical education. (4 months)

Phase 2: Utilising focused ethnography, an exploration of the culturally grounded experiences of dyslexic foundation doctors will be performed. This aims to generate a rich description of their world in relation to safe and effective prescribing. (12 months)

Phase 3: This will entail the creation and validation of an online questionnaire, using the findings from the ethnographic study. The main aim of this survey will be to quantify qualitative findings. (6 months)

Phase 4: This will entail the distribution and analysis of the online questionnaire nationally to dyslexic medical students and foundation doctors (8 months).

Phase 5: Analysis of data, thesis write up and publications. (6 months)

Support

The doctoral candidate will benefit from a diverse supervisory team and the supportive collaboration of John Anderson. Our backgrounds and interests span across medicine, disability studies, critical autism studies, sociology, medical education, social justice, and participatory research. Our supervisory team includes lived experience of neurodivergence. SS (second supervisor) is dyslexic/autistic/ADHD. We strive to create a supportive, neurodiversity-affirmative research/educational environment.

Applicants

We encourage applications from a wide range of backgrounds, not just medical/healthcare. We particularly encourage applications from those with social science backgrounds and/or those with previous experience in ethnography or wider qualitative research approaches. We also actively encourage applications from neurodivergent candidates. 

How to apply

In order to apply, please visit the University of Brighton website, and select “Doctoral College” as the School. You should then select the project that you wish to apply for. 

Interviews will take place on Wednesday 17 April.

Funding Notes

This is a 3-year PhD studentship funded by Brighton and Sussex Medical funded, starting on 1st October 2024. Funding will cover tuition fees for UK students (at the Home rate), a stipend at the UKRI rate and a research allowance which will cover research running costs. International applicants are welcome to apply but will be required to cover the difference between Home and International fees.

References

  • Kennedy MB, Haq I, Ferns G, Williams SE, Okorie M. The role of undergraduate teaching, learning and a national prescribing safety assessment in preparation for practical prescribing: UK medical students' perspective. Br J Clin Pharmacol. 2019 Oct;85(10):2390-2398.
  • Shaw SCK, Okorie M, Anderson JL. Safe and effective prescribing with dyslexia: a collaborative autoethnography. The Qualitative Report. 2022;27(6):1710-29.
  • Shaw SCK, Hennessy LR, Anderson JL. The learning experiences of dyslexic medical students during the COVID-19 pandemic: a phenomenological study. Advances in Health Sciences Education: Theory and Practice. 2022;27(1):107-24.
  • Hennessy LR, Shaw SCK, Anderson JL. Medical students’ attitudes towards and beliefs about dyslexia: a single-centre survey study. International Journal of Social Sciences & Educational Studies. 2020;7(4):69-79.
  • Anderson JL, Shaw SCK. The experiences of medical students and junior doctors with dyslexia: a survey study. International Journal of Social Sciences & Educational Studies. 2020;7(1):62-71.
  • Shaw SCK, Hennessy LR, Okorie M, Anderson JL. Safe and effective prescribing with dyslexia. BMC Medical Education. 2019;19(1):277.
  • Shaw SCK, Anderson JL. The experiences of medical students with dyslexia: an interpretive phenomenological study. Dyslexia. 2018;24(3):220-33.
  • Shaw SCK, Malik M, Anderson JL. The exam performance of medical students with dyslexia: a review of the literature. MedEdPublish. 2017; 6(3): 2.
  • Shaw SC, Anderson JL, Grant AJ. Studying medicine with dyslexia: a collaborative autoethnography. The Qualitative Report. 2016; 21(11): 2036-54.
BACKGROUND IMAGE FOR PANEL

Characterising and targeting chemo-resistant acute myeloid leukaemia (AML) cells utilising a novel in vitro model of the bone marrow microenvironment

Supervisors: Dr Eleni Ladikou, Prof Andrea Pepper, Dr Fabio Simoes

Application deadline: Friday 12 April 2024 

About the Project

Applications are invited for a 3.5-year funded PhD studentship at Brighton and Sussex Medical School.

Project details

Acute myeloid leukaemia (AML) is the most common type of acute leukaemia in adults, with its incidence increasing with age1. According to Cancer Research UK, there are 3000 new cases each year and 2700 deaths2. AML remains a therapeutic challenge due to its aggressiveness and genetic/phenotypic heterogeneity3, 4. Although 80% of patients can initially achieve a complete remission, the long-term disease-free survival (DFS) is only 40% at 6 years with a 10% 5-year survival rate from first relapse 5. Therefore, relapse after initial response to chemotherapy remains a serious clinical challenge requiring new therapeutic strategies.

The persistence of chemo-resistant cells in the protective bone marrow (BM) microenvironment (BMME) following standard therapies is a key challenge that must be overcome to enable successful treatment of AML patients The aim of the project is to characterise these chemo-resistant AML cells and identify novel druggable targets to increase their vulnerability to therapy.

We have already developed an in vitro multi-cellular co-culture system that mirrors the adhesive and chemo-protective nature of the AML BMME; the BMAS (PhD Dr Eleni Ladikou). Using this system, we have demonstrated that a proportion of adherent AML cells remain viable in the presence of the commonly utilised chemotherapeutic agent, cytarabine. Utilising the BMAS, the successful candidate will identify novel and specific druggable pathways that can be leveraged to increase the vulnerability of this resistant cell population to therapy. They will use multiple approaches to achieve this, including transcriptomics (scRNA sequencing), phenotypic characterisation (flow cytometry) and functional assays (differentiation markers, cell cycle, proliferation and colony forming unit assays) in both cell lines and primary patient cells. The aim is to find either a common target within different patients or potentially patient-specific targets. Finally, the impact of modulating identified targets on the resistant leukaemic cells will be tested in vitro using targeting therapies (if they are available), or siRNA knock-down.

Research Environment

The successful candidate will be integrated into the rapidly expanding haemato-oncology team at BSMS led by Professors Chris and Andrea Pepper working closely with the computational biology team led by Dr Simon Mitchell and Dr Fabio Simoes, who leads the in vivo work. The project will be co-supervised by Dr Eleni Ladikou, Professor Andrea Pepper (who supervised Dr Ladikou’s PhD) and the team’s new lecturer, Dr Fabio Simoes. Dr Ladikou, who established the system to be used in the project, is uniquely placed to lead this study and impart the knowledge and expertise she gained during her PhD studies to the successful candidate. Furthermore, she is a clinical academic and will be ideally placed to recruit AML patients into the study.

The candidate will also integrate into the Haematology Research Group, which spans the University of Sussex, University of Brighton and BSMS.  The project offers a wide range of training opportunities, and the student will be able to acquire essential skills from a variety of areas including cell biology, cell signalling, drug targeting bioinformatics, and translational haemato-oncology. This should provide the successful candidate with critical skills and substantial experience to make them a highly competitive candidate for a postdoctoral research position, especially in the field of translational oncology. The candidate will also have the opportunity to engage with patients and their families at research open days and the clinical team at the Royal Sussex County Hospital and Eastbourne hospital, who will help obtain patient samples for laboratory experiments.

Entry requirements

This studentship starting on 1 October 2024 is suitable for those with background in biological, cancer sciences or a related discipline. We invite applications from students who hold, or expect to obtain, a first or upper second-class undergraduate degree or equivalent, in an appropriate subject, from a recognised academic institution. This studentship is only open to UK citizens or EU citizens who have pre-settled or settled status.

How to apply

Applicants must apply through the University’s application portal where they can submit a CV and complete the application form. Please select “Doctoral College” as the School, and select the studentship listed in order to apply. The deadline for applications is 12 April 2024. Interviews will be held in May 2024. Informal enquiries are welcome and should be submitted to Dr Eleni Ladikou (eleni.ladikou@nhs.net). Please note, this studentship is one of three studentships being simultaneously advertised by researchers within the Haematology Research Group. We welcome parallel applications to these exciting training opportunities.

Funding Notes

This is a 3.5-year PhD studentship funded by Brighton and Sussex Medical School and Sussex Cancer Fund, starting on 1st October 2024. Funding will cover tuition fees for UK students (at the Home rate), a stipend at the UKRI rate and a research allowance which will cover research running costs. International applicants are welcome to apply but will be required to cover the difference between Home and International fees.

References

  1. Schlenk RF. Acute myeloid leukemia: Introduction to a series highlighting progress and ongoing challenges. Haematologica. 2023 Feb 1; 108(2):306-7.
  2. UK CR. [Internet]. [accessed 2023 14/04]. Available here >
  3. Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B et al. Genetically distinct leukemic stem cells in human cd34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med. 2016 Jul 25; 213(8):1513-35.
  4. Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A et al. Clonal heterogeneity of acute myeloid leukemia treated with the idh2 inhibitor enasidenib. Nat Med. 2018 Aug; 24(8):1167-77.
  5. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG et al. Randomized comparison of dat versus ade as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the medical research council's 10th aml trial (mrc aml10). Adult and childhood leukaemia working parties of the medical research council. Blood. 1997 Apr 1; 89(7):2311-8.
BACKGROUND IMAGE FOR PANEL

Understanding how AML cells subvert the bone marrow microenvironment in order to develop rational therapeutic interventions

Supervisors: Dr Fabio Simoes, Prof Andrea Pepper, Dr Simon Mitchell 

Application deadline: Friday 12 April 2024 

Funded PhD Project (UK Students Only)

About the Project

Applications are invited for a fully funded 3-year PhD studentship at Brighton and Sussex Medical School.

Project details

Acute myeloid leukaemia (AML) is the most common acute leukaemia, accounting for approximately 80% of cases. Despite continued efforts, the prognosis of AML remains a challenge, with the 5-year survival rate being approximately 15% (Cancer Research UK). AML is marked by a disruption in myeloid cell maturation, leading to the build-up of immature cells within the bone marrow microenvironment (BMME). The dynamic interplay between leukaemic cells and the BMME transforms the latter into a cancer-supporting milieu, which substantially contributes to therapy resistance. AML displays notable heterogeneity, and while the significance of the interplay with the BMME has garnered attention, it is not known whether the critical BMME changes that occur during the disease process are common features or patient specific.

The aim of the project is to establish whether AML prompts heterogeneous BMME remodelling or whether there are recurrent changes, which offer opportunities to develop targeted therapeutic interventions for the benefit of patients.

To achieve this, an in vitro co-culture of AML cells with stromal cells will be used as a platform for phospho-kinase arrays, cytokine arrays and RNA sequencing to identify signalling and transcriptional changes in the stroma in response to AML cells. These data will be used to identify promising new drug targets which will be tested in the co-culture system. This project provides an exciting opportunity for the successful candidate to learn a variety of widely applicable techniques and contribute towards finding novel therapeutic targets in this frequently incurable disease.  

Research Environment

The successful candidate will integrate into a rapidly expanding and multidisciplinary haemato-oncology group at BSMS consisting of teams led by Dr Fabio Simoes, Professors Chris and Andrea Pepper and Dr Simon Mitchell. These groups are also part of a wider vibrant and active Haematology Research Group which consists of teams from the University of Sussex, University of Brighton and BSMS.  The project provides diverse training opportunities, enabling the student to gain crucial skills across various areas such as cell biology, cell signalling, drug targeting, computational biology, and translational haemato-oncology. This exposure aims to equip the prospective candidate with essential expertise and significant experience, enhancing their competitiveness for a postdoctoral research role, particularly within the realm of translational oncology.

Entry requirements

This studentship is suitable for those with background in biological, cancer sciences or another relevant subject area. We invite applications from students who have received or are on target to achieve a relevant undergraduate degree with minimum 2:1 classification (or equivalent). An MSc and previous laboratory experience are desirable but not essential.

Applicants must apply through the University’s application portal where they can submit a CV and complete the application form. Please select “Doctoral College” as the School, where the studentship will be listed. The deadline for applications is 12 April 2024. Interviews will be held in May 2024. Informal enquiries are welcome and should be submitted to Dr Fabio Simoes (F.A.Simoes@bsms.ac.uk). Please note, this studentship is one of three studentships being simultaneously advertised by researchers within the Haematology Research Group. We welcome parallel applications to these exciting training opportunities.

Funding Notes

This is a 3-year PhD studentship funded by Brighton and Sussex Medical funded, starting on 1st October 2024. Funding will cover tuition fees for UK students (at the Home rate), a stipend at the UKRI rate and a research allowance which will cover research running costs. International applicants are welcome to apply but will be required to cover the difference between Home and International fees.

References

  1. Ladikou, E. E., Sivaloganathan, H., Pepper, A. & Chevassut, T. Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia. Curr. Oncol. Rep. 22, 27 (2020).
  2. Ladikou, E. E., Chevassut, T., Pepper, C. J. & Pepper, A. G. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. Br. J. Haematol. 189, 815–825 (2020).
  3. Méndez-Ferrer, S. et al. Bone marrow niches in haematological malignancies. Nat Rev Cancer 20, 285–298 (2020)

PhD studentships now recruited

  • Coping Strategy Enhancement - adapting the intervention for the treatment of hallucinations in the context of dementia
  • Developing a co-designed brief, low cost and scalable intervention for student carer mental health and wellbeing
  • Optimising infection prevention and control in healthcare settings through applied genomics and prediction
  • Determining the role of long non-coding RNA in the pathogenisis of high-risk gain(1q) positive, multiple myeloma
  • Detection and characterisation of non-tuberculous mycobacteria (NTM)
  • Development of a new treatment for osteoarthritis
  • Substance use in relation to the mental and sexual heath of vulnerable adolescents and young adults under 25 in coastal areas of Kent and Sussex 
  • The mental health and wellbeing needs of looked after and displaced children in southeast England 
  • Helping young people to live successfully with long-term health issues
  • Resourcing Resilience: Positive psychology among adolescents living with HIV 
  • Widening access to psychological interventions for diverse communities: exploring the potential of community-led interventions 
  • Co-producing stigma-proof mental health interventions with and for newcomers (asylum seekers, refugees and migrants) in southeast England 
  • Defining Mycobacterium tuberculosis in lung tissue – a novel discovery platform for new vaccine and drug targets
  • Epidemiology of cancer in the elderly (aged > 65 years) in England
  • The roles of oxidative stress and redox regulation in chronic inflammatory disease (Supervisors: Dr Lisa Mullen, Prof Pietro Ghezzi, Prof Kevin Davies)
  • Pillars of Expertise: Visual Perception & Memory (Supervisors: Dr Natasha Sigala, Prof Mara Cercignani
  • Investigating the genetic basis of osteosarcoma in children & dogs (Supervisors: Prof Sarah Newbury, Dr Peter Bush, Dr Chris Jones)
  • The embodiment of unconscious knowledge in maladaptive behaviour (Supervisors: Prof Hugo Critchley, Dr Sarah Garfinkel, Prof Dora Duka)
  • Can simulation clarify diagnostic skills for newly qualified doctors? (Supervisors: Dr Inam Haq, Dr Wesley Scott-Smith)
  • Impact of oxytocin on emotional regulation in binge drinking and alcoholism: behavioural, physiological and fMRI investigations (Supervisors: Prof Hugo Critchley, Prof Dora Duka)
  • Developing an algorithm for predicting children with severe asthma (Supervisors: Prof Somnath Mukhopadhyay, Dr Katy Fidler)
  • Development of a refined model of neuropathic pain: a model without frank nerve injury (Supervisors: Dr Andrew Dilley, Prof Pietro Ghezzi)
  • Role of secreted oxidoreductases in osteoarthritis, rheumathoid arthritis and systemic lupus erythematosus (Supervisors: Prof Pietro Ghezzi, Dr Manuela Mengozzi)
  • Measuring quality of life in severe dementia: validation of DEMQOL-Proxy in family and professional carers of people with severe dementia (Prof Sube Banerjee, Prof Naji Tabet)
  • Stigma in health care: Does it influence the way general practitioners record consultations? (Supervisors: Dr Elizabeth Ford, Prof Helen Smith, Prof Flis Henwood)
  • Interoception and preventative intervention for anxiety in adults with autism (supervisors: Dr Sarah Garfinkel, Prof Hugo Critchley)